Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
Provided By GlobeNewswire
Last update: Apr 10, 2025
– SRC recommended that the trial escalate to the next dose level of 30mg capsule –
– No dose-limiting toxicities (DLT’s) or rash observed to date –
Read more at globenewswire.com
